

David S Schade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8101097/publications.pdf>

Version: 2024-02-01

35
papers

457
citations

1040056

9
h-index

752698

20
g-index

35
all docs

35
docs citations

35
times ranked

418
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholesterol Review: A Metabolically Important Molecule. <i>Endocrine Practice</i> , 2020, 26, 1514-1523.	2.1	83
2	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 867-874.	8.6	61
3	The Temporal Relationship between Endogenously Secreted Stress Hormones and Metabolic Decompensation in Diabetic Man*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980, 50, 131-136.	3.6	59
4	Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. <i>Diabetes, Obesity and Metabolism</i> , 1999, 1, 199-206.	4.4	44
5	Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>Diabetes Care</i> , 2018, 41, 2495-2501.	8.6	27
6	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 2478-2484.	8.6	19
7	The Role of a Coronary Artery Calcium Scan in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 594-603.	4.4	18
8	The Application of the LDL Principle. <i>World Journal of Cardiovascular Diseases</i> , 2016, 06, 109-125.	0.2	12
9	Ten pivotal questions about diabetic ketoacidosis. <i>Postgraduate Medicine</i> , 2001, 110, 89-95.	2.0	10
10	A Simplified Approach to Reducing Cardiovascular Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6033-6039.	3.6	10
11	Resolving the Egg and Cholesterol Intake Controversy: New Clinical Insights Into Cholesterol Regulation by the Liver and Intestine. <i>Endocrine Practice</i> , 2022, 28, 102-109.	2.1	10
12	Prevention of Coronary Heart Disease: A Translational Clinical Challenge. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 11-23.	0.2	9
13	Abnormal Coronary Artery Calcium Scans in Asymptomatic Patients. <i>American Journal of Medicine</i> , 2017, 130, 394-397.	1.5	8
14	Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. <i>Journal of Lipid Research</i> , 2018, 59, 872-883.	4.2	8
15	A Feasible, Simple, Cost-Saving Program to End Cardiovascular Disease in the United States. <i>American Journal of Medicine</i> , 2019, 132, 1365-1367.	1.5	8
16	Prescribing Statins to Reduce Cardiovascular Disease: 10 Common Misconceptions. <i>American Journal of Medicine</i> , 2019, 132, 897-899.	1.5	8
17	Should Routine Screening for Coronary Artery Disease Be Recommended? A Comparison With Routine Screening for Colon Cancer. <i>American Journal of Medicine</i> , 2020, 133, 155-157.	1.5	7
18	Stop Stenting; Start Reversing Atherosclerosis. <i>American Journal of Medicine</i> , 2021, 134, 301-303.	1.5	7

#	ARTICLE	IF	CITATIONS
19	A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. <i>Endocrine Practice</i> , 2020, 26, 787-793.	2.1	6
20	Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaque—Provided by the Society for the Prevention of Symptomatic Heart Disease. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 320-341.	0.2	6
21	The ketotic effects of glucocorticoid and growth hormone in man. <i>Acta Diabetologica Latina</i> , 1980, 17, 161-170.	0.2	5
22	THE KETOTIC RATIO (KB/NEFA) IN MAN. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1981, 8, 303-313.	1.9	5
23	To Pump or Not to Pump. <i>Diabetes Technology and Therapeutics</i> , 2005, 7, 845-848.	4.4	5
24	Management of Asymptomatic Patients With Positive Coronary Artery Calcium Scans. <i>Journal of the Endocrine Society</i> , 2017, 1, 588-599.	0.2	5
25	Risk Factors for Hearing Impairment in Type 1 Diabetes. <i>Endocrine Practice</i> , 2019, 25, 1243-1254.	2.1	5
26	Insulin Timing: A Patient-Centered Approach To Improve Control In Type 1 Diabetes. <i>Endocrine Practice</i> , 2017, 23, 471-478.	2.1	4
27	The Role of Catecholamines in Metabolic Acidosis. <i>Novartis Foundation Symposium</i> , 1982, 87, 235-253.	1.1	3
28	Prevention of Statin Overtreatment and Increased Patient Compliance in High-Cardiovascular-Risk Individuals. <i>American Journal of Medicine</i> , 2019, 132, 1123-1125.	1.5	2
29	The Rationale for a Different Approach to Preventing Cardiovascular Disease. <i>World Journal of Cardiovascular Diseases</i> , 2019, 09, 489-510.	0.2	2
30	Repaglinide Dose Response? A Clinician's Viewpoint. <i>Diabetes Technology and Therapeutics</i> , 1999, 1, 257-258.	4.4	1
31	Challenging Opinions. <i>Postgraduate Medicine</i> , 1988, 83, 72-78.	2.0	0
32	The Reply. <i>American Journal of Medicine</i> , 2020, 133, e324-e325.	1.5	0
33	The Reply. <i>American Journal of Medicine</i> , 2020, 133, e536-e537.	1.5	0
34	The Reply. <i>American Journal of Medicine</i> , 2021, 134, e585.	1.5	0
35	Extending Coronary Artery Calcium Scanning with CT Coronary Angiography in the Primary Care Setting. <i>American Journal of Medicine</i> , 2022, , .	1.5	0